Safety signals with Nintedanib: Case series exploring the adverse effects of Nintedanib in interstitial lung disease
Fuente:
Zenodo
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Recurso digital |
| Language: | English |
| Published: |
Zenodo
2025
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866901316770463744 |
|---|---|
| author | Gopika, G Kodiattu, Sara Kurien Harikrishnan, S R S, Jacob Jesurun |
| author_facet | Gopika, G Kodiattu, Sara Kurien Harikrishnan, S R S, Jacob Jesurun |
| contents | <p>Nintedanib, a Tyrosine Kinase Inhibitor (TKI) with antifibrotic properties, has been approved for the treatment of Idiopathic Pulmonary Fibrosis (IPF), chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype and systemic sclerosis- associated ILD (SSc -ILD). Gastrointestinal (GI) adverse effects and Transaminitis were reported commonly with its use. This case series narrates the clinical experiences of patients treated with Nintedanib and highlights the role of Nintedanib in ILD management while emphasizing the need for careful monitoring to optimize safety and treatment outcomes.</p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_17556394 |
| institution | Zenodo |
| language | eng |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Safety signals with Nintedanib: Case series exploring the adverse effects of Nintedanib in interstitial lung disease Gopika, G Kodiattu, Sara Kurien Harikrishnan, S R S, Jacob Jesurun Nintedanib Tyrosine kinase Inhibitor Interstitial Lung disease Idiopathic Pulmonary Fibrosis Transient Transaminitis Hyponatremia <p>Nintedanib, a Tyrosine Kinase Inhibitor (TKI) with antifibrotic properties, has been approved for the treatment of Idiopathic Pulmonary Fibrosis (IPF), chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype and systemic sclerosis- associated ILD (SSc -ILD). Gastrointestinal (GI) adverse effects and Transaminitis were reported commonly with its use. This case series narrates the clinical experiences of patients treated with Nintedanib and highlights the role of Nintedanib in ILD management while emphasizing the need for careful monitoring to optimize safety and treatment outcomes.</p> |
| title | Safety signals with Nintedanib: Case series exploring the adverse effects of Nintedanib in interstitial lung disease |
| topic | Nintedanib Tyrosine kinase Inhibitor Interstitial Lung disease Idiopathic Pulmonary Fibrosis Transient Transaminitis Hyponatremia |
| url | https://doi.org/10.5281/zenodo.17556394 |